If you want to address civilization and society's issues, then you have to do it with the city," Urban Partners' co-CEO Claus ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic Helfgott, said in an interview.

Novo Nordisk's rare disease unit awaits Phase 3 data for etavopivat in sickle cell disease, aiming for 50% VOC reduction ...

Donald Trump’s incoming administration was promising to slash corporate taxes and tear up red tape in the world’s mightiest ...

Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for ...

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

The microbial fermentation technology market is experiencing significant growth, fueled by the increasing incidence of chronic diseases like cancer a ...

While attention has been on Apple’s progress (or lack thereof) in Research Triangle Park, the company continues to spend on a ...

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Private equity firms announced or completed 18 megadeals valued at $5 billion or above in 2024, more than double the prior-year total and the fourth-highest annual tally of PE-backed megadeals since ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...